Varkaris, Andreas <br/><br/>
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2016 
 - 107-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-15-0235  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anilides--pharmacology<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Bone Neoplasms--diagnosis<br/>Cell Line, Tumor<br/>Clinical Trials, Phase II as Topic<br/>Disease Models, Animal<br/>Drug Resistance, Neoplasm<br/>Gene Knockdown Techniques<br/>Humans<br/>Male<br/>Mice<br/>Multicenter Studies as Topic<br/>Neoplasm Staging<br/>Phosphorylation<br/>Positron-Emission Tomography<br/>Prostatic Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Pyridines--pharmacology<br/>Receptor, Fibroblast Growth Factor, Type 1--metabolism<br/>Signal Transduction--drug effects<br/>Treatment Outcome<br/>Tumor Burden--drug effects<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays